通过中断技术进行支气管扩展剂反应,以指导学前喘息的管理
Paul C Seddon1, Rhian Willson2, Catherine Olden2
1Respiratory Care, Royal Alexandra Children's Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, UK seddop@gmail.com.
Archives of disease in childhood
|May 31, 2023
概括
在有反复喘息的学龄前儿童中,支气管扩展剂的反应可以预测吸入性皮质类固醇 (ICS) 的有效性. 测量这种反应可以帮助识别可能受益于ICS治疗的儿童.
科学领域:
- 儿科肺病学 儿科肺病学
- 呼吸系统医学 呼吸系统医学
- 临床过敏 临床过敏
背景情况:
- 在学龄前儿童中,反复出现喘息是诊断的挑战.
- 预测对吸入性皮质类固醇 (ICS) 的反应对于有效的管理至关重要.
- 支气管扩展剂反应 (BDR) 是治疗疗效的潜在生物标志物.
研究的目的:
- 为了研究临床特征和肺功能在喘的学龄前儿童之间的关系.
- 为了确定测量支气管扩展剂反应 (BDR) 是否可以预测ICS治疗的益处.
- 评估中断电阻 (Rint) BDR在指导ICS治疗中的实用性.
主要方法:
- 一项非随机干预研究,涉及有复发性喘息的学龄前儿童 (2至6岁以下).
- 肺功能 (Rint) 和症状得分在多个时间点在支气管扩展剂服用之前和之后被测量.
- 吸入性皮质类固醇 (ICS) 根据症状严重程度开始使用,并评估反应.
主要成果:
- 在ICS治疗后,观察到Rint和每日症状得分显著降低.
- 在ICS启动前呈阳性Rint BDR显著与治疗后症状得分的更大降低有关.
- 修改喘预测指数 (mAPI) 和家长的感知不能可靠地预测ICS反应.
结论:
- 支气管扩展剂的反应,特别是使用中断阻力 (Rint),可以作为一种有价值的工具来选择可能受益于吸入性皮质类固醇 (ICS) 治疗的喘息的学龄前儿童.
- 这一发现支持在儿科呼吸道疾病的临床决策中使用客观的BDR测量.
相关概念视频
Inhaled Medications
323
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
323
Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Drugs Used in Lower Respiratory Disorders: Overview
509
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
509
Antiasthma Drugs: β2-Adrenoceptor Agonists
319
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
319
COPD: Management Using Bronchodilators and Corticosteroids
256
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
256
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K


